Trino Raises $12M for Indane Dimers in Ulcerative Colitis
By Cormac Sheridan
Wednesday, May 29, 2013
DUBLIN, Ireland Trino Therapeutics Ltd., a spinout from Trinity College Dublin (TCD), raised €9 million (US$11.6 million) in a Series A round to move PH46A, an oral, first-in-class indane dimer, into clinical trials in ulcerative colitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.